




ISSP



Histologic and Molecular Implications on Ovarian Cancer Treatment

Wiebke Solass, MD Head of Gynecological Pathology Institute of Pathology University of Bern



No relevant financial relationships.

This presentation and/or comments will provide a balanced, non-promotional, and evidence-based approach to all diagnostic, therapeutic and/or research related content.





Cultural Linguistic Competency (CLC) & Implicit Bias (IB)

STATE LAW:

The California legislature has passed <u>Assembly Bill (AB) 1195</u>, which states that as of July 1, 2006, all Category 1 CME activities that relate to patient care must include a cultural diversity/linguistics component. It has also passed <u>AB 241</u>, which states that as of January 1, 2022, all continuing education courses for a physician and surgeon **must** contain curriculum that includes specified instruction in the understanding of implicit bias in medical treatment.

The cultural and linguistic competency (CLC) and implicit bias (IB) definitions reiterate how patients' diverse backgrounds may impact their access to care.

The following CLC & IB components will be addressed in this presentation:

• Outcome differences depending on access to health care/socioeconomic status.





- Histology: OC is many diseases
- One therapy (Carboplatin + Paclitaxel) fits for all ?
- The challenge of chemoresistance in OC
- Prognostic factors: dealing with complexity
- New opportunities






- Histology: OC is many diseases
- One therapy (Carboplatin + Paclitaxel) fits for all ?
- The challenge of chemoresistance in OC
- Prognostic factors: dealing with complexity
- New opportunities






OC is many diseases








High-grade serous ovarian cancer (HGSOC)








Endometrioid Ovarian Carcinoma (EC)







Clear Cell Ovarian Carcinoma (CCC)








Mucinous Ovarian Carcinoma (MC)










Low-grade serous ovarian cancer (LGSOC)

3%








Prognosis of EOC depends on the histology

PROGRESSION-FREE SURVIVAL

OVERALL SURVIVAL



Winter WE 3rd et al, J Clin Oncol 2007








- Histology: OC is many diseases
- One therapy (Carboplatin + Paclitaxel) fits for all ?
- The challenge of chemoresistance in OC
- Prognostic factors: dealing with complexity
- New opportunities





Treating ovarian cancer remains challenging

- The standard care for OC— a combination of surgery and chemotherapy has remained almost unchanged since the 1960s
- No significant progress in overall survival
 - PARP-inhibitors: mature survival data expected 2023
 - Immune checkpoint inhibitors: disappointing in newly diagnosed OC



Vaughan et al, Nat Rev Cancer 2012





Does one therapy (Carboplatin + Paclitaxel) fit for all?

- Gold standard chemotherapy regimen (upfront) = Carboplatin + Paclitaxel
 - 70-80% of OC patients show initial response
 - 50-75% of responders relapse within 18 months after completing first-line therapy
 - Only 10% to 15% of patients who present with advanced disease experience long-term remission
- Lack of valid tools to predict whether they will be primary platinum resistant or not prior to chemotherapy


Paracchini et al, Oncotarget 2016; Herzog TJ, Clin Cancer Res 2004, Arora et al Oncologist 2021, Li et al Front Oncol 2022






Does one therapy (Carboplatin + Paclitaxel) fit for all?





"Taking a rigorous view, the ovarian histotypes should be regarded as distinct diseases, as their cell of origin, epidemiology, and driver mutations are quite different" Vaughan et al, Nat Rev Cancer 2012,







- Histology: OC is many diseases
- One therapy (Carboplatin + Paclitaxel) fits for all ?
- The challenge of chemoresistance in OC
- Prognostic factors: dealing with complexity
- New opportunities






The challenge of chemoresistance in OC

Similar overall survival times, yet divergent progression-free survival times, between treated and untreated patients, may reflect the competitive release of aggressive subclones

Platinum-resistant ovarian cancer has a median survival of 9–12 months and less than 15% respond to subsequent chemotherapy.




McGranahan et al, Cell 2017, Davis et al. Gynec Oncol 2014, Paracchini et al, Oncotarget 2021





Competitive Release of Resistance Subclones in OC

- In type 1 and Type 2 OC:
 - The genomic profile of a single tumor biopsy taken from the ovary is not representative
 - Relapsed disease arises probably not from new mutations but from resistant clones originally present in one of the primary lesions
 - The outgrowth of resistant subclones is favored by the selective pressure of standard chemotherapeutic treatment



71 tumor biopsies taken from 12 HGSOC and 7 non-HGSOC, at the time of primary surgery (chemonaive tumor) and after chemotherapy. Targeted NGS sequencing (65 genes). Phylogenetic tree.


Paracchini et al, Oncotarget 2021





Whole-genome characterization of chemoresistant HGSOC

- Inactivation of the tumor suppressors RB1, NF1, RAD51B, and PTEN
- CCNE1 amplification common in refractory HGSOC
- Acquired resistance associated with:
 - reversions of germline BRCA1 or BRCA2 mutations
 - loss of BRCA1 promoter methylation
 - overexpression of the drug efflux pump MDR1



92 women with primary refractory, resistant, sensitive and matched acquired resistant HGSOC Whole-genome sequencing of tumor and germline DNA samples





- Histology: OC is many diseases
- One therapy (Carboplatin + Paclitaxel) fits for all ?
- The challenge of chemoresistance in OC
- Prognostic factors: dealing with complexity
- New opportunities





οξψμορον


Diagnosis means generalization, ignoring the individual

Prognosis means individualization, looking at the individual





22




- Histology: OC is many diseases
- One therapy (Carboplatin + Paclitaxel) fits for all ?
- The challenge of chemoresistance in OC
- Prognostic factors: dealing with complexity
- New opportunities





Multimodal data integration using machine learning improves risk stratification of HGSOC




Boehm et al Nature Cancer 2022





Weakly supervised deep learning accurately infers HGSOC tissue type on H&E




Boehm et al Nature Cancer 2022







Interpretable histopathological features stratify HGSOC patients by OS




Boehm et al Nature Cancer 2022





27

Multimodal integration improves stratification and identifies clinically significant subgroups











Conclusion

- The prognosis of OC depends on the histology and the molecular landscape
- Should start to adapt the treatment regimen according to that
- AIML can improve the stratification and identification of clinically significant subgroups





- Histology: OC is many diseases
- One therapy (Carboplatin + Paclitaxel) fits for all ?
- The challenge of chemoresistance in OC
- Prognostic factors: dealing with complexity
- New opportunities



